Also, another study including 90 T2D patients on GLP‐1 RAs or dipeptidyl peptidase 4 inhibitors (DPP4i) reported that 36% of GLP‐RAs users had elevated serum amylase or lipase levels,27 and the large‐scale Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial reported that after usage of GLP‐1 RAs, over 22.7% of patients had elevated enzyme levels at baseline28; although a meta‐analysis of trials indicated a slight, albeit nonsignificant elevation in pancreatitis risk associated with GLP‐1 RAs.29 This evidence concerns the gene GLP1R and diabetes mellitus.